The University of Chicago Header Logo

Connection

Mark J. Ratain to National Cancer Institute (U.S.)

This is a "connection" page, showing publications Mark J. Ratain has written about National Cancer Institute (U.S.).
  1. Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest? Nat Biotechnol. 2023 Nov; 41(11):1517-1519.
    View in: PubMed
    Score: 0.225
  2. Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2015 Nov 15; 21(22):5057-63.
    View in: PubMed
    Score: 0.130
  3. Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res. 2014 Aug 15; 20(16):4210-7.
    View in: PubMed
    Score: 0.119
  4. The investigational drug steering committee. Clin Adv Hematol Oncol. 2007 Oct; 5(10):779-80.
    View in: PubMed
    Score: 0.074
  5. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6.
    View in: PubMed
    Score: 0.024
  6. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1764-9.
    View in: PubMed
    Score: 0.022
  7. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.